<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">CyM4RYsLyfDSMgmFnHVStZd</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2024000700502</article-id>
      <article-id pub-id-type="other">00502</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20240002</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Cient&#237;fica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>O Risco de Doen&#231;a Cardiovascular Segundo o Escore N&#227;o Laboratorial da OMS em uma Popula&#231;&#227;o Brasileira Selecionada: Percentis da Distribui&#231;&#227;o e Concord&#226;ncia com o Escore Laboratorial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1051-9434</contrib-id>
          <name>
            <surname>Cesena</surname>
            <given-names>Fernando Yue</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1010-2428</contrib-id>
          <name>
            <surname>Generoso</surname>
            <given-names>Giuliano</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3212-8466</contrib-id>
          <name>
            <surname>Santos</surname>
            <given-names>Itamar de S.</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Alexandre C.</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bittencourt</surname>
            <given-names>Marcio S.</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Raul D.</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lotufo</surname>
            <given-names>Paulo A.</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Obten&#231;&#227;o de financiamento</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bense&#241;or</surname>
            <given-names>Isabela M.</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Obten&#231;&#227;o de financiamento</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Instituto Dante Pazzanese de Cardiologia</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgdiv2">Centro de Pesquisa Cl&#237;nica e Epidemiol&#243;gica</institution>
        <institution content-type="orgdiv1">Hospital Universit&#225;rio</institution>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Centro de Pesquisa Cl&#237;nica e Epidemiol&#243;gica, Hospital Universit&#225;rio, Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgdiv1">Genetics Department</institution>
        <institution content-type="orgname">Harvard Medical School</institution>
        <addr-line>
          <named-content content-type="city">Boston</named-content>
          <named-content content-type="state">Massachusetts</named-content>
        </addr-line>
        <country country="US">EUA</country>
        <institution content-type="original">Genetics Department, Harvard Medical School, Boston, Massachusetts &#8211; EUA</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution content-type="orgdiv1">Heart and Vascular Institute</institution>
        <institution content-type="orgname">University of Pittsburgh Medical Center</institution>
        <addr-line>
          <named-content content-type="city">Pittsburgh</named-content>
          <named-content content-type="state">Pennsylvania</named-content>
        </addr-line>
        <country country="US">EUA</country>
        <institution content-type="original">Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania &#8211; EUA</institution>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas da Faculdade de Medicina</institution>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Instituto do Cora&#231;&#227;o (InCor), Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <institution content-type="orgname">Hospital Israelita Albert Einstein</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"><bold>Correspond&#234;ncia: Fernando Yue Cesena</bold> &#8226; Instituto Dante Pazzanese de Cardiologia &#8211; Se&#231;&#227;o de Hipertens&#227;o, Tabagismo e Nefrologia &#8211; Av. Dr. Dante Pazzanese, 500. CEP 04012-909, S&#227;o Paulo, SP &#8211; Brasil. E-mail: <email>fernando.cesena@dantepazzanese.org.br</email> </corresp>
        <fn fn-type="conflict">
          <p>Potencial conflito de interesse</p>
          <p>N&#227;o h&#225; conflito com o presente artigo</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Editor respons&#225;vel pela revis&#227;o: Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>26</day>
        <month>08</month>
        <year>2024</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2024</year>
      </pub-date>
      <volume>121</volume>
      <issue>7</issue>
      <elocation-id>e20240002</elocation-id>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>01</month>
          <year>2024</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>04</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>05</month>
          <year>2024</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Doen&#231;as Cardiovasculares</kwd>
        <kwd>Fatores de Risco de Doen&#231;as Card&#237;acas</kwd>
        <kwd>&#205;ndice de Massa Corporal</kwd>
        <kwd>Medi&#231;&#227;o de Risco</kwd>
        <kwd>Organiza&#231;&#227;o Mundial da Sa&#250;de</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 06 0010.00 RS</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 06 0212.00 BA</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 060300.00 ES</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 06 0278.00 MG</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 06 0115.00 SP</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>01 06 0071.00 RJ</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>Em 2019, a Organiza&#231;&#227;o Mundial da Sa&#250;de (OMS) publicou gr&#225;ficos revisados para estimar o risco de doen&#231;as cardiovasculares (DCV) em 10 anos.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Foram propostos dois modelos: um baseado em exames laboratoriais incluindo colesterol total plasm&#225;tico e presen&#231;a ou aus&#234;ncia de diabetes mellitus como preditores, e outro baseado no &#237;ndice de massa corporal (IMC). Em locais onde recursos s&#227;o escassos e em situa&#231;&#245;es de consult&#243;rio em que os n&#237;veis de colesterol e informa&#231;&#245;es sobre diabetes n&#227;o est&#227;o dispon&#237;veis, o escore baseado no IMC pode ser usado.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Em um estudo anterior, determinamos percentis da distribui&#231;&#227;o do risco de DCV da OMS laboratorial, de acordo com sexo e idade, na linha de base da popula&#231;&#227;o do Estudo Longitudinal de Sa&#250;de do Adulto (ELSA-Brasil).<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Esses percentis foram associados ao risco calculado de DCV ateroscler&#243;tica at&#233; 75 anos, independentemente do risco estimado em 10 anos. A express&#227;o do percentil de risco tem sido proposta para aumentar a conscientiza&#231;&#227;o do risco e melhorar a ades&#227;o &#224;s medidas preventivas.<sup><xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref></sup></p>
      <p>Neste estudo, buscamos (1) determinar percentis espec&#237;ficos para sexo e idade da distribui&#231;&#227;o do risco de DCV pelo escore n&#227;o laboratorial da OMS na popula&#231;&#227;o brasileira e (2) avaliar a concord&#226;ncia entre os escores de risco de DCV laboratorial e n&#227;o laboratorial da OMS.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todo</title>
      <p>Este estudo &#233; uma an&#225;lise transversal dos dados basais do ELSA-Brasil, coletados no per&#237;odo de 2008 a 2010. O ELSA-Brasil &#233; uma coorte prospectiva de 15.105 funcion&#225;rios de etnias mistas de universidades p&#250;blicas e institui&#231;&#245;es de pesquisa em seis cidades brasileiras.<sup><xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Foram inclu&#237;dos participantes de 40 a 74 anos e exclu&#237;dos aqueles que apresentavam infarto do mioc&#225;rdio, acidente vascular encef&#225;lico ou procedimentos de revasculariza&#231;&#227;o pr&#233;vios. O protocolo do ELSA-Brasil foi aprovado pelo comit&#234; de &#233;tica de cada institui&#231;&#227;o participante e todos os participantes deram consentimento informado por escrito.</p>
      <p>A hipertens&#227;o foi considerada como press&#227;o arterial sist&#243;lica &#8805;140 mmHg, press&#227;o arterial diast&#243;lica &#8805;90 mmHg ou uso de medica&#231;&#227;o para controle da press&#227;o arterial. Diabetes mellitus foi definida como diagn&#243;stico autorreferido, uso de medica&#231;&#227;o espec&#237;fica, glicemia em jejum &#8805;126 mg/dL, hemoglobina glicada &#8805;6,5% ou glicemia de 2 horas &#8805;200 mg/dL ap&#243;s carga de 75 g em teste oral de toler&#226;ncia &#224; glicose. Defini&#231;&#245;es detalhadas das demais vari&#225;veis relatadas neste estudo podem ser encontradas em outras publica&#231;&#245;es.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Os n&#237;veis plasm&#225;ticos de colesterol total e o IMC foram categorizados de acordo com os grupos usados no c&#225;lculo do risco de DCV da OMS.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>O risco de um primeiro evento de DCV fatal ou n&#227;o fatal em 10 anos (relacionado a doen&#231;a coronariana ou acidente vascular encef&#225;lico) foi calculado usando os escores de risco de DCV da OMS atualizados em 2019, calibrados para a Am&#233;rica Latina Tropical.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Para estabelecer percentis da distribui&#231;&#227;o do escore de risco de DCV n&#227;o laboratorial da OMS, primeiramente ordenamos todos os valores poss&#237;veis do risco calculado dentro de cada faixa et&#225;ria. Em seguida, determinamos o percentil de distribui&#231;&#227;o correspondente a cada escore. Foram realizadas an&#225;lises separadas para cada sexo.</p>
      <p>O teste do sinal foi aplicado para comparar os escores de risco, uma vez que as diferen&#231;as entre as observa&#231;&#245;es pareadas n&#227;o eram sim&#233;tricas. Um valor de p &lt; 0,05 foi considerado estatisticamente significativo. A concord&#226;ncia entre os valores de risco foi avaliada pelos diagramas de Bland-Altman. Todas as an&#225;lises foram realizadas utilizando o software R e Microsoft Excel. O pacote do R Shiny foi utilizado para desenvolver uma aplica&#231;&#227;o web para c&#225;lculo do risco de DCV em 10 anos e o percentil correspondente para sexo e idade.</p>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>A popula&#231;&#227;o do estudo (n = 13.366) foi caracterizada por maior presen&#231;a feminina (55%) e idade mediana (intervalo interquartil [IQR]) de 52 (46, 59) anos (<ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Figura Complementar 1, Tabela Complementar 1</ext-link>).</p>
      <p>A <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Figura Complementar 2</ext-link> mostra a distribui&#231;&#227;o do risco predito de DCV em 10 anos de acordo com sexo e faixa et&#225;ria, enquanto as <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Tabelas Complementares de 2 a 8</ext-link> apresentam os percentis dessa distribui&#231;&#227;o. Esses percentis permitiram o desenvolvimento de gr&#225;ficos de risco versus percentil, de acordo com sexo e faixa et&#225;ria (<xref ref-type="fig" rid="f01">Figura 1</xref>).</p>
      <p>
        <fig id="f01">
          <label>Figura 1</label>
          <caption>
            <title>&#8211; Percentis da distribui&#231;&#227;o do risco predito de doen&#231;a cardiovascular (DCV) em 10 anos, de acordo com sexo e faixa et&#225;ria. O risco de DCV foi calculado pelo escore de risco n&#227;o laboratorial da Organiza&#231;&#227;o Mundial da Sa&#250;de.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-121-07-e20240002-40002-gf01.tif"/></fig>
      </p>
      <p>Na amostra total, o risco baseado no IMC foi ligeiramente inferior ao risco baseado em exames laboratoriais (mediana [IQR] 3% [2%, 5%] versus 4% [2%, 6%], respectivamente, p &lt;0,001). A <xref ref-type="fig" rid="f02">Figura 2</xref> mostra a concord&#226;ncia entre os escores de risco laboratorial e n&#227;o laboratorial em mulheres e homens. Os escores coincidiram na maioria dos participantes (7.884 [59%]). A diferen&#231;a entre os valores (risco laboratorial menos risco n&#227;o laboratorial) variou entre -3% e 7% para as mulheres e entre -5% e 17% para os homens.</p>
      <p>
        <fig id="f02">
          <label>Figura 2</label>
          <caption>
            <title>&#8211; Diagramas de Bland-Altman para a concord&#226;ncia entre os escores de risco de DCV laboratorial e n&#227;o laboratorial da OMS, de acordo com o sexo. A linha azul representa a m&#233;dia de todas as diferen&#231;as (escores laboratoriais menos escores n&#227;o laboratoriais), enquanto as linhas vermelha e verde representam os limites de concord&#226;ncia de 95% inferior e superior, respectivamente. DCV: doen&#231;a cardiovascular.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-121-07-e20240002-40002-gf02.tif"/></fig>
      </p>
      <p>As <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Figuras Complementares 3 a 5</ext-link> mostram a concord&#226;ncia entre escores de risco laboratorial e n&#227;o laboratorial, de acordo com subgrupos de interesse. Entre os indiv&#237;duos sem diabetes mellitus, os valores foram iguais em 7.873 (70,5%), enquanto o risco laboratorial foi numericamente superior ao risco baseado no IMC em 2.176 (99,5%) participantes com diabetes. Quanto maior o n&#237;vel de colesterol total e menor o IMC, maior foi a tend&#234;ncia para um risco laboratorial mais elevado em compara&#231;&#227;o com o risco n&#227;o laboratorial.</p>
      <p>Uma aplica&#231;&#227;o web para calcular riscos de DCV e percentis por sexo e idade pode ser acessada em <ext-link ext-link-type="uri" xlink:href="https://bit.ly/3sGsIgK">https://bit.ly/3sGsIgK</ext-link>. Um c&#243;digo R para criar novas vari&#225;veis para o risco de DCV da OMS baseado em dados laboratoriais ou no IMC em um conjunto de dados, al&#233;m dos percentis correspondentes para sexo e idade, est&#225; dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="https://bit.ly/3Pov250">https://bit.ly/3Pov250</ext-link>.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>A avalia&#231;&#227;o do risco de DCV com base no IMC &#233; uma op&#231;&#227;o quando exames de colesterol e glicemia n&#227;o est&#227;o dispon&#237;veis,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> podendo ser um m&#233;todo mais simples para os membros da comunidade calcularem o seu pr&#243;prio risco. Nossos achados indicam que o risco baseado no IMC coincide com o risco laboratorial na maioria das circunst&#226;ncias, mas pode ser substancialmente menor na presen&#231;a de diabetes mellitus e colesterol total muito elevado. Pode-se fazer a hip&#243;tese de que o risco n&#227;o baseado em laborat&#243;rio subestima o risco real nestes subgrupos de alto risco. No entanto, conclus&#245;es definitivas n&#227;o podem ser feitas, uma vez que m&#233;tricas de desempenho dos escores n&#227;o foram avaliadas. Observamos tamb&#233;m que o risco baseado no IMC tende a ser menor do que o escore laboratorial &#224; medida que o IMC diminui. O escore com melhor precis&#227;o entre indiv&#237;duos com baixo IMC permanece uma quest&#227;o em aberto.</p>
      <p>As limita&#231;&#245;es deste estudo incluem o fato de a popula&#231;&#227;o estudada n&#227;o ser representativa da popula&#231;&#227;o brasileira, com maior propor&#231;&#227;o feminina, mais brancos e menos pardos em compara&#231;&#227;o com o Censo Brasileiro de 2022.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Al&#233;m disso, esta an&#225;lise de concord&#226;ncia pode n&#227;o ser aplicada a outras popula&#231;&#245;es com caracter&#237;sticas demogr&#225;ficas diferentes. Por fim, deve-se ressaltar que o c&#225;lculo do risco representa apenas o primeiro passo na estratifica&#231;&#227;o do risco de DCV, e a pr&#225;tica cl&#237;nica tamb&#233;m deve considerar diversos outros fatores e avalia&#231;&#227;o da aterosclerose subcl&#237;nica.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
      <p>Para concluir, este estudo estabeleceu percentis da distribui&#231;&#227;o do risco de DCV da OMS n&#227;o baseado em laborat&#243;rio por sexo e idade na popula&#231;&#227;o brasileira. Em compara&#231;&#227;o com a estrat&#233;gia baseada em laborat&#243;rio, a abordagem n&#227;o laboratorial leva ao mesmo escore de risco na maioria dos indiv&#237;duos, mas tende a subestimar o risco em homens, indiv&#237;duos com diabetes, LDL-c mais elevado ou IMC mais baixo.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. WHO CVD Risk Chart Working Group. World Health Organization Cardiovascular Disease Risk Charts: Revised Models to Estimate Risk in 21 Global Regions. Lancet Glob Health. 2019;7(10):1332-45. doi: 10.1016/S2214-109X(19)30318-3.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>WHO CVD Risk Chart Working Group</collab>
          </person-group>
          <article-title>World Health Organization Cardiovascular Disease Risk Charts: Revised Models to Estimate Risk in 21 Global Regions</article-title>
          <source>Lancet Glob Health</source>
          <year>2019</year>
          <volume>7</volume>
          <issue>10</issue>
          <fpage>1332</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="doi">10.1016/S2214-109X(19)30318-3</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. World Health Organization. HEARTS Technical Package for Cardiovascular Disease Management in Primary Health Care: Risk Based CVD Management. Geneva: World Health Organization; 2020.</mixed-citation>
        <element-citation publication-type="report">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>HEARTS Technical Package for Cardiovascular Disease Management in Primary Health Care: Risk Based CVD Management</source>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Cesena FY, Generoso G, Santos IS, Duncan BB, Ribeiro ALP, Brant LC, et al. Percentiles of Predicted 10-Year Cardiovascular Disease Risk by Sex and Age in Brazil and their Association with Estimated Risk of Long-term Atherosclerotic Events. Prev Med. 2023;177:107755. doi: 10.1016/j.ypmed.2023.107755.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cesena</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Generoso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Percentiles of Predicted 10-Year Cardiovascular Disease Risk by Sex and Age in Brazil and their Association with Estimated Risk of Long-term Atherosclerotic Events</article-title>
          <source>Prev Med</source>
          <year>2023</year>
          <volume>177</volume>
          <size units="pages">107755</size>
          <pub-id pub-id-type="doi">10.1016/j.ypmed.2023.107755</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Navar AM, Pencina MJ, Mulder H, Elias P, Peterson ED. Improving Patient risk Communication: Translating Cardiovascular Risk into Standardized Risk Percentiles. Am Heart J. 2018;198:18-24. doi: 10.1016/j.ahj.2017.12.005.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Navar</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Pencina</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Improving Patient risk Communication: Translating Cardiovascular Risk into Standardized Risk Percentiles</article-title>
          <source>Am Heart J</source>
          <year>2018</year>
          <volume>198</volume>
          <fpage>18</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ahj.2017.12.005</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Cesena FY, Kashiwagi NM, Minanni CA, Santos RD. Determining Percentiles of Atherosclerotic Cardiovascular Risk According to Sex and Age in a Healthy Brazilian Population. Arq Bras Cardiol. 2023;120(6):e20220552. doi: 10.36660/abc.20220552.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cesena</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Kashiwagi</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Minanni</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Determining Percentiles of Atherosclerotic Cardiovascular Risk According to Sex and Age in a Healthy Brazilian Population</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2023</year>
          <volume>120</volume>
          <issue>6</issue>
          <elocation-id>e20220552</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20220552</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Aquino EM, Barreto SM, Bensenor IM, Carvalho MS, Chor D, Duncan BB, et al. Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): Objectives and Design. Am J Epidemiol. 2012;175(4):315-24. doi: 10.1093/aje/kwr294.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aquino</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bensenor</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Chor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>BB</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): Objectives and Design</article-title>
          <source>Am J Epidemiol</source>
          <year>2012</year>
          <volume>175</volume>
          <issue>4</issue>
          <fpage>315</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="doi">10.1093/aje/kwr294</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Schmidt MI, Duncan BB, Mill JG, Lotufo PA, Chor D, Barreto SM, et al. Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil). Int J Epidemiol. 2015;44(1):68-75. doi: 10.1093/ije/dyu027.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Mill</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Lotufo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Chor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>SM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil)</article-title>
          <source>Int J Epidemiol</source>
          <year>2015</year>
          <volume>44</volume>
          <issue>1</issue>
          <fpage>68</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1093/ije/dyu027</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Instituto Brasileiro de Geografia e Estat&#237;stica. Panorama do Censo 2022 [Internet]. Rio de Janeiro: Instituto Brasileiro de Geografia e Estat&#237;stica; 2022. Available from: <ext-link ext-link-type="uri" xlink:href="https://censo2022.ibge.gov.br/panorama/index.html">https://censo2022.ibge.gov.br/panorama/index.html</ext-link>.</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Instituto Brasileiro de Geografia e Estat&#237;stica</collab>
          </person-group>
          <source>Panorama do Censo 2022</source>
          <comment>Internet</comment>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Instituto Brasileiro de Geografia e Estat&#237;stica</publisher-name>
          <year>2022</year>
          <ext-link ext-link-type="uri" xlink:href="https://censo2022.ibge.gov.br/panorama/index.html">https://censo2022.ibge.gov.br/panorama/index.html</ext-link>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):1082-143. doi: 10.1161/CIR.0000000000000625.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grundy</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Beam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Birtcher</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>RS</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>
          <source>Circulation</source>
          <year>2019</year>
          <volume>139</volume>
          <issue>25</issue>
          <fpage>1082</fpage>
          <lpage>1143</lpage>
          <pub-id pub-id-type="doi">10.1161/CIR.0000000000000625</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <label/>
        <p>Vincula&#231;&#227;o acad&#234;mica</p>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other">
        <label/>
        <p>Aprova&#231;&#227;o &#233;tica e consentimento informado</p>
        <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Hospital Universit&#225;rio da USP sob o n&#250;mero de protocolo CEP-HU 669/06, CAAE: 0016.1.198.000-06. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#237;dos no estudo.</p>
      </fn>
      <fn fn-type="supplementary-material" id="fn_ast1">
        <label>*</label>
        <p>Material suplementar</p>
        <p>Para informa&#231;&#227;o adicional, por favor, <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">clique aqui</ext-link>.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>Fontes de financiamento</p>
        <p>O presente estudo foi parcialmente financiado por Minist&#233;rio da Sa&#250;de, Departamento de Ci&#234;ncia e Tecnologia (DECIT); Minist&#233;rio da Ci&#234;ncia, Tecnologia e Inova&#231;&#227;o, Financiadora de Estudos e Projetos (Financiadora de Estudos e Projetos [Finep]); e o Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq), sob os processos 01 06 0010.00 RS, 01 06 0212.00 BA, 01 060300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP e 01 06 0071.00 RJ.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20240002i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The WHO Cardiovascular Disease Risk (Non-Laboratory-Based) in a Selected Brazilian Population: Percentiles of Distribution And Agreement With Laboratory-Based Scores</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1051-9434</contrib-id>
          <name>
            <surname>Cesena</surname>
            <given-names>Fernando Yue</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis and Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1010-2428</contrib-id>
          <name>
            <surname>Generoso</surname>
            <given-names>Giuliano</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3212-8466</contrib-id>
          <name>
            <surname>Santos</surname>
            <given-names>Itamar de S.</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Alexandre C.</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bittencourt</surname>
            <given-names>Marcio S.</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff4001">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Raul D.</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff5001">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6001">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lotufo</surname>
            <given-names>Paulo A.</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Obtaining financing</role>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bense&#241;or</surname>
            <given-names>Isabela M.</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Obtaining financing</role>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o Paulo, SP &#8211; Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Centro de Pesquisa Cl&#237;nica e Epidemiol&#243;gica, Hospital Universit&#225;rio, Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
      </aff>
      <aff id="aff3001">
        <label>3</label>
        <country country="US">USA</country>
        <institution content-type="original">Genetics Department, Harvard Medical School, Boston, Massachusetts &#8211; USA</institution>
      </aff>
      <aff id="aff4001">
        <label>4</label>
        <country country="US">USA</country>
        <institution content-type="original">Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania &#8211; USA</institution>
      </aff>
      <aff id="aff5001">
        <label>5</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Instituto do Cora&#231;&#227;o (InCor), Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
      </aff>
      <aff id="aff6001">
        <label>6</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001"><bold>Mailing Address: Fernando Yue Cesena</bold> &#8226; Instituto Dante Pazzanese de Cardiologia &#8211; Se&#231;&#227;o de Hipertens&#227;o, Tabagismo e Nefrologia &#8211; Av. Dr. Dante Pazzanese, 500. Postal Code 04012-909, S&#227;o Paulo, SP &#8211; Brazil. E-mail: fernando.cesena@dantepazzanese.org.br </corresp>
        <fn fn-type="conflict">
          <p>Potential conflict of interest</p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Editor responsible for the review: Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Cardiovascular Diseases</kwd>
        <kwd>Heart Disease Risk Factors</kwd>
        <kwd>Body Mass Index</kwd>
        <kwd>Risk Assessment</kwd>
        <kwd>World Health Organization</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>In 2019, the World Health Organization (WHO) published revised charts for estimating the 10-year risk of cardiovascular disease (CVD).<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Two models are proposed: one based on laboratory tests including plasma total cholesterol and presence or absence of diabetes mellitus as predictors, and another based on the body mass index (BMI). In low-resource and office settings, when cholesterol levels and information on diabetes are not available, the BMI-based score can be used.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>In a previous study, we determined laboratory-based percentiles of the WHO CVD risk distribution, according to sex and age, in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) baseline population.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> These percentiles were associated with the calculated risk of atherosclerotic CVD up to 75 years, regardless of the estimated 10-year risk. Expressing the risk percentile has been proposed to increase risk awareness and improve adherence to preventive measures.<sup><xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref></sup></p>
        <p>In this study, we sought to (1) determine sex- and age-specific percentiles of the distribution of the WHO non-laboratory-based CVD risk in the Brazilian population and (2) evaluate the agreement between WHO laboratory- and non-laboratory-based CVD risk scores.</p>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <p>This study is a cross-sectional analysis of ELSA-Brasil baseline data collected from 2008 to 2010. ELSA-Brasil is a prospective cohort of 15,105 racially mixed employees from public universities and research institutions in six Brazilian cities.<sup><xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> We included participants from 40 to 74 years old and excluded those with previous myocardial infarction, stroke, or revascularization procedures. The protocol for ELSA-Brasil was approved by the ethics committee of each participating institution, and all participants provided written informed consent.</p>
        <p>Hypertension was considered in the presence of systolic blood pressure &#8805;140 mmHg, diastolic blood pressure &#8805;90 mmHg, or the use of medication to control blood pressure. Diabetes mellitus was defined as a self-reported diagnosis, use of specific medication, fasting blood glucose &#8805;126 mg/dL, glycated hemoglobin &#8805;6.5%, or a 2-hour blood glucose &#8805;200 mg/dL after 75 g load on oral glucose tolerance test. Detailed definitions of other variables reported in this study can be found elsewhere.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Plasma total cholesterol levels and BMI were categorized according to the groups used for the WHO CVD risk calculation.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>Ten-year risk of experiencing a first fatal or nonfatal CVD event (related to coronary heart disease or stroke) was computed using the 2019 Updated WHO CVD risk charts calibrated for Tropical Latin America.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>To establish percentiles of the WHO non-laboratory-based CVD risk score distribution, we first sorted all possible values of the calculated risk within each age group. Then, we determined the distribution percentile corresponding to each score. Separate analyses were performed for each sex.</p>
        <p>The sign test was applied to compare risk scores once differences between paired observations were not symmetric. A p-value &lt; 0.05 was considered statistically significant. Agreement between risk values was assessed using Bland-Altman diagrams. All analyses were performed using R software and Microsoft Excel. The Shiny R package was used to develop a web application for calculating the 10-year CVD risk and the corresponding percentile for sex and age.</p>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p>The study population (n = 13,366) was characterized by a higher female presence (55%) and a median age (interquartile range [IQR]) of 52 (46, 59) years (<ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Supplemental Figure 1</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Supplemental Table 1</ext-link>).</p>
        <p><ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Supplemental Figure 2</ext-link> shows the predicted 10-year CVD risk distribution according to sex and age group, while <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Supplemental Tables 2 to 8</ext-link> report the percentiles of such distribution. These percentiles enabled the construction of risk-versus-percentile plots according to sex and age group (<xref ref-type="fig" rid="f01001">Figure 1</xref>).</p>
        <p>
          <fig id="f01001">
            <label>Figure 1</label>
            <caption>
              <title>&#8211; Percentiles of the predicted 10-year cardiovascular disease (CVD) risk distribution, according to sex and age group. The CVD risk was calculated using the non-laboratory-based risk score from the World Health Organization.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-121-07-e20240002-40002-gf01-en.tif"/></fig>
        </p>
        <p>Overall, the BMI-based risk was slightly lower than the risk based on laboratory exams (median [IQR] 3% [2%, 5%] versus 4% [2%, 6%], respectively, p &lt;0.001). <xref ref-type="fig" rid="f02001">Figure 2</xref> shows the agreement between laboratory- and non-laboratory-based risk scores in females and males. The scores agreed in most participants (7,884 [59%]). The difference between the values (laboratory-based risk minus non-laboratory-based risk) ranged from -3% to 7% in females and from -5% to 17% in males.</p>
        <p>
          <fig id="f02001">
            <label>Figure 2</label>
            <caption>
              <title>&#8211; Bland-Altman diagrams for the agreement between WHO laboratory- and non-laboratory-based CVD risk scores according to sex. The blue line represents the mean of all differences (laboratory- minus non-laboratory-based scores), while the red and green lines represent the lower and the upper 95% limits of agreement, respectively. CVD: cardiovascular disease.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-121-07-e20240002-40002-gf02-en.tif"/></fig>
        </p>
        <p><ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">Supplemental Figures 3 to 5</ext-link> depict the agreement between laboratory- and non-laboratory-based risk scores according to subgroups of interest. Among individuals without diabetes mellitus, the values were the same in 7,873 (70.5%), whereas the laboratory-based risk was numerically higher than the BMI-based risk in 2,176 (99.5%) participants with diabetes. The higher the total cholesterol level and the lower the BMI, the greater the tendency for a higher laboratory-based risk compared to non-laboratory-based risk.</p>
        <p>A web application for calculating CVD risks and percentiles by sex and age can be accessed at <ext-link ext-link-type="uri" xlink:href="https://bit.ly/3sGsIgK">https://bit.ly/3sGsIgK</ext-link>. An R code for creating new variables for WHO laboratory- and BMI-based CVD risks and the corresponding percentiles for sex and age in a dataset is available at <ext-link ext-link-type="uri" xlink:href="https://bit.ly/3Pov250">https://bit.ly/3Pov250</ext-link>.</p>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>BMI-based CVD risk assessment serves as an option when cholesterol level and glycemic exams are unavailable<sup><xref ref-type="bibr" rid="B2">2</xref></sup> and may offer community members a simpler method to calculate their own risk. Our findings indicate that BMI-based risk generally agrees with laboratory-based risk, but may be substantially lower in the presence of diabetes mellitus and very high total cholesterol. It is feasible to hypothesize that the non-laboratory-based risk score underestimates actual risk in these high-risk subgroups. However, definitive conclusions cannot be drawn once score performance metrics were not evaluated. We also observed that the BMI-based risk tends to be lower than the laboratory-based score as the BMI decreases. The question of which score is more accurate among individuals with low BMI remains unanswered.</p>
        <p>Limitations of this study include the fact that the study population is not representative of the Brazilian population, with a higher female proportion, more white and less brown people compared to the 2022 Brazilian Census.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Moreover, this agreement analysis may not be applicable to other populations with different demographic characteristics. Finally, it must be stressed that risk calculation represents only the first step in CVD risk stratification, and clinical practice should also consider several other factors and evaluation of subclinical atherosclerosis.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
        <p>In conclusion, this study determined percentiles of the WHO non-laboratory-based CVD risk distribution by sex and age in the Brazilian population. Compared to the laboratory-based strategy, the non-laboratory approach leads to the same risk score in most individuals, but tends to underestimate the risk among males, individuals with diabetes, higher LDL-c, or lower BMI.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>Study association</p>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other">
          <p>Ethics approval and consent to participate</p>
          <p>This study was approved by the Ethics Committee of the Hospital Universit&#225;rio da USP under the protocol number CEP-HU 669/06, CAAE: 0016.1.198.000-06. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p>
        </fn>
        <fn fn-type="supplementary-material" id="fn_ast1001">
          <label>*</label>
          <p>Supplemental Materials</p>
          <p>For additional information, please <ext-link ext-link-type="uri" xlink:href="http://abccardiol.org/supplementary-material/2024/12107/2024-0002_CC_supplemental_material.pdf">click here</ext-link>.</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="financial-disclosure">
          <p>Sources of funding</p>
          <p>This study was partially funded by Minist&#233;rio da Sa&#250;de, Departamento de Ci&#234;ncia e Tecnologia (DECIT); Minist&#233;rio da Ci&#234;ncia, Tecnologia e Inova&#231;&#227;o, Financiadora de Estudos e Projetos (Financiadora de Estudos e Projetos [Finep]); e o Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq), sob os processos 01 06 0010.00 RS, 01 06 0212.00 BA, 01 060300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP e 01 06 0071.00 RJ.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
